Case-Based Discussion of Oral Antivirals for COVID-19: Learning from Experience – Part 2 | Fiona Marra, MPharm, MSc

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Case-Based Discussion of Oral Antivirals for COVID-19: Learning from Experience - Part 1 | Catia Marzolini, PharmD, PhD

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Oral Antivirals for COVID-19: How to Best Make Use of Their Therapeutic Effects | Giovanni Di Perri, MD, PhD

Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

Viral dynamics and factors favouring the duration of covid-19 positivity: Evidence from the first-three epidemiological waves in Cameroon - Aurelie Minelle Kengni Ngueko

Approaches to Combat COVID-19 in Low- and Middle-Income Countries Workshop 2022

The “Window of Opportunity”: Harnessing the Pediatric Immune Landscape for Life-Long Vaccine- Elicited Protection | Sallie Permar, MD, PhD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016

Compliance to Hepatitis B Vaccination Guidelines and Development of Seroprotection in Filipino Hepatitis B Susceptible HIV Patients in a Tertiary Hospital Treatment Hub

APACC 2020

Prevalence of Hepatitis B Virus and Vaccine Antibody Titers Among HIV Positive and Negative Infants in Botswana - Lynnette N. Bhebhe

Conference on Liver Disease in Africa (COLDA) 2020

COLDA_2020_abstract_66_Evaluation of the Efficacy of the Egyptian Program for Hepatitis B Virus Vaccination: A Cross Sectional National Survey

Conference on Liver Disease in Africa (COLDA) 2020

HIV Vaccine Pipeline and Progress, Including Broadly Neutralizing Antibodies - Glenda Gray, MBBCh, FCPaed(SA), DSc (Hons)

INTEREST 2019

Starting Long-Acting Drugs in the COVID-19 Era - Anton Pozniak, MD, FRCP

Global HIV Clinical Forum 2020